• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在药物发现价值链中部署持续改进。

Deploying continuous improvement across the drug discovery value chain.

机构信息

Oncology Research Area, Mereside, AstraZeneca R&D Alderley Park, Alderley Edge, UK.

出版信息

Drug Discov Today. 2011 Jun;16(11-12):467-71. doi: 10.1016/j.drudis.2011.03.007. Epub 2011 Apr 3.

DOI:10.1016/j.drudis.2011.03.007
PMID:21443967
Abstract

In addressing the challenges facing pharmaceutical R&D one question is frequently asked: how can continuous improvement (CI), delivered through a Lean Sigma approach, be applied in a research environment to deliver overall benefit? We show that taking a value chain approach to improvement projects in a discovery research organization, initially focusing on the drug discovery project delivery level (i.e. middle layer of the value chain), provides the foundation for an effective CI programme. The adaptation of Lean Sigma principles and methodology, combined with the tenacity and creativity of scientists, enabled the delivery of significant improvements in challenging areas, including target selection, project decision making and the compound design-make-test-analyse (DMTA) cycle.

摘要

在解决制药研发面临的挑战时,人们经常会问一个问题:如何通过精益西格玛方法实现持续改进,并将其应用于研究环境中以实现整体效益?我们表明,在发现研究组织中采取价值链方法来改进项目,最初专注于药物发现项目交付层面(即价值链的中间层),为有效的持续改进计划奠定了基础。精益西格玛原则和方法的调整,加上科学家的坚韧和创造力,使包括目标选择、项目决策和化合物设计-制造-测试-分析(DMTA)周期在内的挑战性领域都取得了重大改进。

相似文献

1
Deploying continuous improvement across the drug discovery value chain.在药物发现价值链中部署持续改进。
Drug Discov Today. 2011 Jun;16(11-12):467-71. doi: 10.1016/j.drudis.2011.03.007. Epub 2011 Apr 3.
2
Creativity, innovation and lean sigma: a controversial combination?创造力、创新和精益西格玛:有争议的组合?
Drug Discov Today. 2011 Jan;16(1-2):50-7. doi: 10.1016/j.drudis.2010.11.005. Epub 2010 Nov 20.
3
Network biology as a new approach to drug discovery.网络生物学作为药物发现的一种新方法。
Curr Opin Drug Discov Devel. 2010 Sep;13(5):524-6.
4
Looking forward in pharmaceutical process chemistry.展望药物过程化学。
Science. 2009 Aug 7;325(5941):701-4. doi: 10.1126/science.1174501.
5
Portfolio management in early stage drug discovery - a traveler's guide through uncharted territory.药物早期发现中的投资组合管理——探索未知领域的旅行指南。
Drug Discov Today. 2011 Jul;16(13-14):609-18. doi: 10.1016/j.drudis.2011.04.012. Epub 2011 May 11.
6
Efficient and effective compound management to support lead optimization.高效且有效的化合物管理以支持先导化合物优化。
J Biomol Screen. 2009 Jun;14(5):523-30. doi: 10.1177/1087057109335747. Epub 2009 May 29.
7
Developing pharmacogenetic evidence throughout clinical development.在临床开发过程中建立药物遗传学证据。
Clin Pharmacol Ther. 2010 Dec;88(6):867-70. doi: 10.1038/clpt.2010.246. Epub 2010 Oct 27.
8
Chemistry strategies in early drug discovery: an overview of recent trends.早期药物发现中的化学策略:近期趋势概述
Drug Discov Today. 2008 Aug;13(15-16):677-84. doi: 10.1016/j.drudis.2008.03.007. Epub 2008 May 2.
9
Value networks identify innovation in 21st century pharmaceutical research.价值网络识别21世纪药物研究中的创新。
Drug Discov Today. 2009 Jan;14(1-2):68-77. doi: 10.1016/j.drudis.2008.09.015. Epub 2008 Nov 20.
10
The role of discovery DMPK scientists in industry: where do we go from here?药物代谢动力学(DMPK)发现阶段科学家在制药行业中的作用:我们将何去何从?
Drug Metab Pharmacokinet. 2012;27(2):169-70.